{"nctId":"NCT00543543","briefTitle":"Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)","startDateStruct":{"date":"2007-09-24","type":"ACTUAL"},"conditions":["Cervical Cancer","Vulvar Cancer","Vaginal Cancer","Genital Warts","Human Papillomavirus Infection"],"count":14840,"armGroups":[{"label":"Low-dose V503","type":"EXPERIMENTAL","interventionNames":["Biological: Experimental: V503"]},{"label":"Mid-dose V503","type":"EXPERIMENTAL","interventionNames":["Biological: Experimental: V503"]},{"label":"High-dose V503","type":"EXPERIMENTAL","interventionNames":["Biological: Experimental: V503"]},{"label":"Gardasil","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: GARDASIL","Biological: Experimental: V503"]}],"interventions":[{"name":"Comparator: GARDASIL","otherNames":[]},{"name":"Experimental: V503","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female between 16- to 26-years-old\n* Has never had Pap testing or has only had normal Pap (Papanicolaou) test results\n* For the immune memory substudy in the extension (Cohort 1): was randomized to V503 in the base study and was in the per-protocol immunogenicity population for ≥1 HPV type\n* For the 3-dose V503 vaccination substudy in the extension (Cohort 2): was randomized to GARDASIL in the base study and received ≥1 dose of GARDASIL\n\nExclusion Criteria:\n\n* History of an abnormal cervical biopsy result\n* History of a positive test for HPV\n* History of external genital/vaginal warts\n* Currently a user of any illegal drugs or an alcohol abuser\n* History of severe allergic reaction that required medical attention\n* Are pregnant\n* Received marketed HPV vaccine or participated in an HPV trial\n* Currently enrolled in a clinical trial\n* Currently has or has a history of certain medical conditions or is currently taking or has taken certain medications (details will be discussed at the time of consent.)","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"16 Years","maximumAge":"26 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis)","description":"HPV Type 31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3), Adenocarcinoma in Situ (AIS), Invasive Cervical Carcinoma, high-grade Vulvar Intraepithelial Neoplasia (VIN 2/3), high-grade Vaginal Intraepithelial Neoplasia (VaIN 2/3), vulvar cancer, or vaginal cancer were determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. This outcome measure reports data based on the protocol-specified plan of conducting hypothesis testing when at least 30 cases had accumulated. The cutoff date for this analysis was 10 April 2013. Disease incidence was defined as the number of primary efficacy cases per 10,000 person-years of follow-up in a treatment arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"15.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (End-of-study Update)","description":"HPV Type 31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3), Adenocarcinoma in Situ (AIS), Invasive Cervical Carcinoma, high-grade Vulvar Intraepithelial Neoplasia (VIN 2/3), high-grade Vaginal Intraepithelial Neoplasia (VaIN 2/3), vulvar cancer, or vaginal cancer were determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. This outcome measure reports cumulative study data through 10 March 2014. Disease incidence was defined as the number of primary efficacy cases per 10,000 person-years of follow-up in a treatment arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"19.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Base Study: Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18/31/33/45/52/58","description":"Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL. Statistical analysis was performed only for HPV types contained in both vaccines.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"893.1","spread":null},{"groupId":"OG001","value":"875.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"666.3","spread":null},{"groupId":"OG001","value":"830.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3131.1","spread":null},{"groupId":"OG001","value":"3156.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"804.6","spread":null},{"groupId":"OG001","value":"678.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"658.4","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"415.9","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"252.8","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379.7","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"482.5","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Extension Study: Geometric Mean Titers to HPV Types 6/11/16/18/31/33/45/52/58 at Predose 4","description":"Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL. This outcome measure applied to Cohort 1 participants only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Base Study: Percentage of Participants With One or More Adverse Event","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.6","spread":null},{"groupId":"OG001","value":"94.2","spread":null},{"groupId":"OG002","value":"92.8","spread":null},{"groupId":"OG003","value":"91.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Base Study: Percentage of Participants With One or More Injection-site Adverse Event","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.7","spread":null},{"groupId":"OG001","value":"90.7","spread":null},{"groupId":"OG002","value":"90.5","spread":null},{"groupId":"OG003","value":"84.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Base Study: Percentage of Participants With One or More Non-injection-site (Systemic) Adverse Event","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null},{"groupId":"OG001","value":"55.8","spread":null},{"groupId":"OG002","value":"51.1","spread":null},{"groupId":"OG003","value":"54.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Base Study: Percentage of Participants With One or More Vaccine-related Adverse Event","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. An AE that is judged by the investigator to be \"definitely related,\" \"probably related,\" or \"possibly related\" to the study drug is defined as a vaccine-related AE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"92.2","spread":null},{"groupId":"OG002","value":"92.8","spread":null},{"groupId":"OG003","value":"87.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Base Study: Percentage of Participants With Study Medication Withdrawn Due to an Adverse Event","description":"An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.1","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Persistent Infection","description":"Combined Incidence of HPV Type 31/33/45/52/58-related persistent infection as determined by clinical/pathologic criteria and positive Polymerase Chain Reaction (PCR) assay for virus subtype. Persistent infection was defined as infection detected in samples from \\>=2 consecutive visits 6 months (+/-1 month visit window) or longer apart. Incidence was defined as the number of cases of persistent infection per 10,000 person-years of follow-up in a treatment arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"538.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Base Study: Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58","description":"Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"50.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"12.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"20.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Extension Study: Geometric Mean Titers to HPV Types 6/11/16/18/31/33/45/52/58 at Day 7 Postdose 4","description":"Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL. This outcome measure applied to Cohort 1 participants only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2180.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2228.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7986.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2399.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1462.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1709.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"323.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1078.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1801.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Extension Study: Geometric Mean Titers to HPV Types 6/11/16/18/31/33/45/52/58 at Day 28 Postdose 4","description":"Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL. This outcome measure applied to Cohort 1 participants only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2585.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2548.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10904.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2907.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1745.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2094.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"440.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1131.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2024.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":310},"commonTop":["Injection site pain","Injection site swelling","Injection site erythema","Headache","Nausea"]}}}